Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies

Next Previous
Trial Profile

A Phase 1 Study of KZR-261, a Small Molecule Sec61 Inhibitor, in Subjects With Advanced Solid Malignancies

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KZR 261 (Primary)
  • Indications Colorectal cancer; Malignant melanoma; Mesothelioma; Prostate cancer; Solid tumours; Uveal melanoma
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Kezar Life Sciences

Most Recent Events

  • 19 Dec 2025 Status changed from active, no longer recruiting to discontinued.
  • 13 Aug 2024 Status changed from recruiting to active, no longer recruiting, according to a Kezar Life Sciences media release.
  • 13 Aug 2024 According to a Kezar Life Sciences media release, full data will be presented at a medical conference following completion of the study. A total of 61 patients enrolled across the dose-escalation and dose expansion portions of the study, which included seven patients enrolled in the melanoma cohort of the dose-expansion portion at a dose level of 60 mg/m2. Enrollment has been stopped in the KZR-261 Phase 1 study, and clinical resources are being reallocated toward development of zetomipzomib.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top